Research and Markets (http://www.researchandmarkets.com/research/rmhv2c/arterial) has announced the addition of the "Arterial Thrombosis - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Arterial Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arterial Thrombosis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Arena Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bayer AG
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Johnson & Johnson
-
Sanofi
Drug Profiles
- AS-1468240
- ASP-1645
- ASP-6537
- BAY-1213790
- BMS-593214
- BMS-654457
- C-3
- E-5539
- ER-410660
- JNJ-375
- Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism
- PZ-128
- SAR-216471
- temanogrel hydrochloride
- ticagrelor
For more information visit http://www.researchandmarkets.com/research/rmhv2c/arterial
View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005464/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular
